Profile data is unavailable for this security.
About the company
Zhejiang Hisun Pharmaceutical Co Ltd is a China-based company primarily engaged in the research, development, production and sales of pharmaceuticals. The Company mainly operates three businesses. The pharmaceutical manufacturing business includes pharmaceutical preparations business, pharmaceutical active pharmaceutical ingredients business and animal medicine business. The pharmaceutical commercial business includes pharmaceutical distribution business, imported pharmaceutical preparations and drug marketing outsourcing business. The emerging business is engaged in research and development in the field of synthetic biology and other businesses. The Company's main products include anti-tumor drugs, anti-infective drugs, cardiovascular drugs, antiparasitic drugs, veterinary drugs, endocrine drugs and other drugs. The Company conducts its business in the domestic and overseas markets.
- Revenue in CNY (TTM)9.84bn
- Net income in CNY546.80m
- Incorporated1998
- Employees7.99k
- LocationZhejiang Hisun Pharmaceutical Co LtdNo. 46, Waisha Road, Jiaojiang DistrictTAIZHOU 318000ChinaCHN
- Phone+86 57 185278141
- Fax+86 57 688827887
- Websitehttps://www.hisunpharm.com
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cansino Biologics Inc | 971.83m | -142.03m | 11.61bn | 1.11k | -- | 3.05 | -- | 11.85 | -0.5455 | -0.5455 | 3.92 | 21.37 | 0.1271 | 0.5861 | 1.38 | 879,482.50 | -1.86 | -4.08 | -2.29 | -5.38 | 78.80 | 45.31 | -14.62 | -27.51 | 3.29 | -- | 0.2242 | -- | 137.01 | 226.43 | 74.45 | -- | 31.38 | -- |
| Mayinglong Pharmaceutical Group Co Ltd | 3.77bn | 571.60m | 11.87bn | 2.65k | 20.74 | 2.76 | -- | 3.14 | 1.33 | 1.33 | 8.75 | 9.97 | 0.7211 | 6.23 | 11.99 | 1,421,812.00 | 11.38 | 10.77 | 13.82 | 13.35 | 46.77 | 42.40 | 15.78 | 14.39 | 4.58 | -- | 0.0226 | 37.31 | 18.85 | 6.62 | 19.14 | 7.97 | 34.47 | 18.98 |
| Jiangxi Tianxin Pharmaceutical Co Ltd | 2.23bn | 617.04m | 12.01bn | 2.68k | 19.40 | 2.51 | -- | 5.40 | 1.42 | 1.42 | 5.11 | 10.93 | 0.3973 | 2.43 | 9.65 | 830,883.10 | 11.01 | 17.10 | 11.88 | 21.16 | 43.04 | 42.99 | 27.72 | 30.12 | 4.31 | -- | 0.0721 | 24.41 | 17.35 | 1.75 | 36.85 | -2.20 | 35.06 | -- |
| Chengdu Easton Biopharmaceuticals Co Ltd | 1.33bn | 241.37m | 12.36bn | 1.52k | 49.18 | 4.16 | -- | 8.97 | 1.37 | 1.37 | 7.55 | 16.23 | 0.3809 | 1.83 | 5.89 | 873,161.50 | 6.92 | 8.09 | 8.44 | 9.82 | 71.90 | 81.72 | 18.16 | 20.10 | 3.12 | -- | 0.0444 | 30.37 | 20.82 | 7.34 | 5.15 | 17.01 | 4.24 | -- |
| Henan Lingrui Pharmaceutical Co., Ltd. | 3.78bn | 799.61m | 12.52bn | 2.44k | 15.57 | 3.83 | -- | 3.29 | 1.41 | 1.41 | 6.67 | 5.73 | 0.711 | 1.89 | 8.06 | 1,553,625.00 | 15.08 | 11.90 | 25.52 | 18.89 | 79.26 | 74.36 | 21.21 | 16.46 | 0.9053 | -- | 0.1379 | 73.97 | 5.72 | 10.17 | 27.19 | 19.67 | 14.29 | 24.57 |
| Zhejiang Hisun Pharmaceutical Co., Ltd. | 9.84bn | 546.80m | 12.68bn | 7.99k | 22.19 | 1.49 | -- | 1.29 | 0.4778 | 0.4778 | 8.61 | 7.10 | 0.623 | 3.08 | 5.32 | 1,230,310.00 | 3.48 | 2.33 | 5.81 | 4.32 | 46.64 | 41.26 | 5.58 | 3.99 | 0.6646 | 5.33 | 0.2803 | 29.47 | -5.65 | -2.44 | 745.24 | 45.22 | -26.03 | 33.24 |
| Beijing Foyou Pharma Co Ltd | 3.42bn | 463.07m | 12.90bn | 3.64k | 27.03 | 3.39 | -- | 3.74 | 0.9863 | 0.9863 | 7.28 | 7.87 | 0.733 | 3.27 | 9.59 | 938,316.50 | 9.99 | 12.53 | 12.82 | 17.64 | 65.17 | 68.01 | 13.62 | 13.02 | 2.52 | -- | 0.0077 | 33.16 | 3.17 | 7.28 | -0.0188 | 17.44 | 35.29 | -- |
| Shenzhen Chipscreen Biosciences Co Ltd | 850.99m | 7.28m | 12.95bn | 1.06k | 1,746.50 | 7.69 | -- | 14.96 | 0.0179 | 0.0179 | 2.09 | 4.06 | 0.2441 | 2.40 | 4.06 | 802,822.70 | 0.2089 | 0.0036 | 0.2479 | 0.0042 | 85.48 | 91.31 | 0.8557 | 0.0181 | 1.79 | -0.6319 | 0.4834 | 0.00 | 25.63 | 30.51 | -228.97 | -- | 15.08 | -- |
| Tibet Rhodiola Pharmaceutical Holding Co | 2.72bn | 981.20m | 13.80bn | 596.00 | 14.01 | 3.87 | -- | 5.05 | 3.04 | 3.04 | 8.44 | 11.02 | 0.5188 | 1.38 | 6.52 | 4,564,666.00 | 18.84 | 14.99 | 25.61 | 19.30 | 92.08 | 92.11 | 36.31 | 23.95 | 2.89 | -- | 0.1971 | 52.89 | -10.45 | 17.45 | 31.26 | 27.47 | -5.16 | 27.43 |
Data as of Feb 11 2026. Currency figures normalised to Zhejiang Hisun Pharmaceutical Co Ltd's reporting currency: Chinese Yuan Renminbi CNY
3.20%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| China Southern Asset Management Co., Ltd.as of 30 Jun 2025 | 8.36m | 0.77% |
| China Asset Management Co., Ltd.as of 30 Jun 2025 | 6.27m | 0.57% |
| GF Fund Management Co., Ltd.as of 30 Jun 2025 | 3.74m | 0.34% |
| The Vanguard Group, Inc.as of 07 Jan 2026 | 3.32m | 0.30% |
| Fullgoal Fund Management Co., Ltd.as of 30 Jun 2025 | 3.14m | 0.29% |
| Galaxy Asset Management Co., Ltd.as of 30 Jun 2025 | 2.41m | 0.22% |
| Shanghai Guotai Junan Securities Assets Management Co., Ltd.as of 30 Jun 2025 | 2.35m | 0.22% |
| Dimensional Fund Advisors LPas of 08 Jan 2026 | 2.06m | 0.19% |
| Bosera Asset Management Co., Ltd.as of 30 Jun 2025 | 1.77m | 0.16% |
| Chang Xin Asset Management Co., Ltd.as of 30 Jun 2025 | 1.57m | 0.14% |
More ▼
Data from 30 Jun 2025 - 05 Feb 2026Source: FactSet Research Systems Inc.
